Swiss Biotech Success Stories with new jury members

Friday, February 26, 2021 @ 10:00 am

Since 2018, the Swiss Biotech Association has been honoring outstanding achievements with the Swiss Biotech Success Stories Awards. Innovative companies, entrepreneurs and scientists are recognized by the industry association for their significant successes and lasting contributions to the Swiss biotech industry. Stefanie Flückiger-Mangual, Seraina Gross and Daniela Marino have now joined the Swiss Biotech Success Stories jury.

The biotech industry is one of the most innovative industries in Switzerland. More than 1,000 start-ups and SMEs develop new medicines (drugs, diagnostics, vaccines) or offer services in these fields. The industry has created around 50,000 jobs with very high economic value and invests around 1.5 billion Swiss francs annually in the research and development of new therapeutic options. Since 2018, the Swiss Biotech Success Stories Awards have highlighted and honored the most important achievements of the industry. Award winners are individuals or companies with significant scientific, medical or commercial achievements that have created sustainable value in Switzerland, in terms of innovative medicines, scientific advances or the creation of new jobs.

An independent jury of experts chaired by Luca Bolliger, Vice President of the Swiss Biotech Association, decides on the Swiss Biotech Success Story Awards each year. New jury members are Stefanie Flückiger-Mangual, CEO and Co-Founder of Tolremo Therapeutics, Seraina Gross, business journalist at Handelszeitung, and Daniela Marino, CEO and Co-Founder of Cutiss. They are replacing Martine Clozel, Co-Founder of Actelion and Idorsia, and Birgit Voigt, journalist at NZZ am Sonntag.

«We are excited to work with Stefanie, Daniela and Seraina. As CEOs of biotech companies and experienced business journalist, respectively, they contribute valuable, complementary knowledge to the jury», explains jury president Luca Bolliger. «At the same time, we thank Martine and Birgit for their important and valuable contributions in launching the Swiss Biotech Success Stories.»

Further jury members of the Swiss Biotech Success Stories are Patrick Aebischer, Entrepreneur and former President of EPFL; Gabrielle Gache, President of the Swiss Healthcare Licensing Group and Chief Business Development and Market Access Officer at OM Pharma; Ulrich Geilinger, Head of Private Equity at HBM Partners; Jürg Zürcher, Biotechnology leader Germany, Switzerland, Austria at Ernst & Young. Thomas Staffelbach, communications consultant for pharma/biotech, is secretary of the jury.

More about the Swiss Biotech Success Stories

More about the Swiss Biotech Success Stories Award jury

You May Also Be Interested In

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We recently noticed fraudulent emails to steal your passwords of your Microsoft, Outlook or similar accounts via phishing emails. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals will ask y
October 8, 2024

Nouscom: Patient enrollment of study for metastatic colorectal cancer completed

Primary efficacy endpoint readout expected in mid-2025 Phase 1b studies in dMMR/MSI GI tumors showed that NOUS-209 with pembrolizumab was well-tolerated, generating potent and broad immune responses and durable tumor shrinkage NOUS-209 is being evaluated in multiple clinical studies targeting MSI cancers, from early-stage cancer interception through to metastatic disease
November 19, 2024

InSphero awarded major EU grant for diversity in 3D in vitro testing

InSphero, the global leader in scalable and reliable 3D in vitro cell culture solutions for drug discovery, takes a leading role in the recently awarded Chips JU European UNLOOC Project to advance its technology platform and address diversity in drug efficacy and safety testing.
November 18, 2024

Ymmunobio honored with 3rd place at the Prix Galien USA Awards

Ymmunobio is proud to announce its recent recognition at the prestigious Prix Galien USA Awards, where the company achieved a 3rd-place honor. The Prix Galien Award acknowledges Ymmunobio’s dedication to advancing science and healthcare.
November 15, 2024

Pharvaris: 3rd quarter 2024 financial results and business updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the
November 13, 2024

Aurealis Therapeutics: CHF 8M for chronic wounds studies and oncology program

Funds will be used to complete Phase 2 RCTs with AUP-16 for Chronic Wounds, and accelerate the development of AUP-55 for ovarian, peritoneal and bladder cancer.
November 13, 2024